At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 805 enrolled
Drug / intervention
Tislelizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti-PD1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen
In Brief
A Phase 3 clinical trial evaluating Tislelizumab and Docetaxel for Non-small Cell Lung Cancer. Completed, enrolled 805 participants across 121 sites in 10 countries.
Detailed Summary
The purpose of this study is to show that tislelizumab will improve overall survival in participants with Stage IIIB or IV non-small cell lung cancer when compared to docetaxel in second or third-line treatment setting.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesBrazil, Bulgaria, China, Lithuania, Mexico, New Zealand, Poland, Russia, Slovakia, Turkey (Türkiye)
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedDec 2017
Primary CompletionJul 2021
Study CompletionJan 2024
TodayJul 2026
First PostedDec 2, 2017
Enrollment StartNov 30, 2017
Primary CompletionJul 15, 2021
Study CompletionJan 18, 2024
TodayJul 1, 2026
Enrollment to primary: 3.6 yearsPosted 8.6 years ago
Interventions
Tislelizumabdrug
Tislelizumab administered by intravenous (IV) infusion
Docetaxeldrug
Docetaxel administered as an IV infusion over 1 hour